# IGF-1 LR3

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/igf-1-lr3 (not this .md URL, and keep its path as given).

- Published: 2026-08-28
- Author: Best Health IQ
- Summary: A long-acting analog of IGF-1 with enhanced receptor binding and extended half-life for anabolic and recovery effects.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/igf-1-lr3

\*\*Insulin-like Growth Factor-1 Long R3\*\* · Hormone & GH · Moderate Evidence · Research Only A long-acting analog of IGF-1 with enhanced receptor binding and extended half-life for anabolic and recovery effects. ### Competition Status Prohibited in competition. This compound is on the WADA Prohibited List (class \[S0 / S2.3 / S2\]), banned at all times, both in and out of competition. Athletes subject to WADA or USADA testing should not use it. ### Description IGF-1 LR3 is a recombinant analog of insulin-like growth factor-1 with an arginine substitution at position 3 and an N-terminal 13 amino acid extension. These modifications reduce binding to IGF-binding proteins, extending its half-life from ~12 minutes to ~20 hours and enhancing its biological activity. ### Key Characteristics - \*\*Molecular Formula:\*\* C400H625N111O115S9 - \*\*Molecular Weight:\*\* 9117.5 Da - \*\*Half-Life:\*\* ~20 hours - \*\*Administration Routes:\*\* Subcutaneous injection, Intramuscular injection - \*\*Typical Dose:\*\* 20–100 mcg - \*\*Frequency:\*\* Daily or every other day - \*\*Cycle Length:\*\* 4–6 weeks (with breaks) ### Investigated Benefits - Enhanced muscle protein synthesis - Accelerated muscle recovery - Improved body composition - Anti-aging effects - Neuroprotection \\\* Benefits based on preclinical/animal research unless otherwise noted. ### Mechanism of Action IGF-1 LR3 binds to IGF-1 receptors throughout the body, activating PI3K/Akt and MAPK signaling pathways that promote cell growth, protein synthesis, and anti-apoptotic effects. It stimulates satellite cell activation for muscle repair and promotes glucose uptake. ### Dosing Protocol - \*\*Typical Dose:\*\* 20–100 mcg - \*\*Frequency:\*\* Daily or every other day - \*\*Cycle Length:\*\* 4–6 weeks (with breaks) - \*\*Administration:\*\* Subcutaneous injection \*\*Protocol Notes:\*\* Use in short cycles (4–6 weeks) with equal breaks to prevent receptor desensitization. Post-workout injection maximizes anabolic effects. Monitor blood glucose — can cause hypoglycemia. ### Reconstitution Guide Add 1 mL bacteriostatic water to 1 mg vial → 1000 mcg/mL For 50 mcg dose: draw 0.05 mL (5 units on U-100 syringe) ### Storage Information Lyophilized: refrigerate. Reconstituted: refrigerate and use within 14 days. ### Quality & Sourcing Standards When sourcing IGF-1 LR3 for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Research Highlights 1. Extended half-life vs native IGF-1 demonstrated in pharmacokinetic studies 2. Enhanced anabolic effects in multiple animal models 3. Neuroprotective effects in CNS injury models ### Evidence Level \*\*Moderate Evidence\*\* — Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited. ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.